However, preliminary data from our laboratory have shown that treating an AML FLT3+ cell line, MOLM-14, in vitro with mTORC1 and mTORC2 does not induce cell death but significantly inhibits cell proliferation (unpublished data). Here, FLT3 is linked to acute myeloid leukemia.